Eosinophilic gastrointestinal diseases make a name for themselves: A new consensus statement with updated nomenclature

Wright, Benjamin L.; Schwartz, Justin T.; Ruffner, Melanie A.; Furuta, Glenn T.; Gonsalves, Nirmala; Dellon, Evan S.; Aceves, Seema S.

doi:10.1016/j.jaci.2022.05.012

Cited by 6 publications

(3 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…He exhibited short stature and failure to thrive from infancy (Fig 1). At age 2 years, he developed palpebral edema with hypoalbuminemia in addition to diarrhea and was diagnosed with EGIDs, that is, eosinophilic gastritis (EoG) and duodenitis (EoD), 9 based on the histological findings. His symptoms underwent repeated exacerbation and remission.…”

Section: Resultsmentioning

confidence: 99%

STAT6 gain-of-function variant exacerbates multiple allergic symptoms

Takeuchi

Yanagi

Takada

et al. 2023

Journal of Allergy and Clinical Immunology

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 99%

STAT6 gain-of-function variant exacerbates multiple allergic symptoms

Takeuchi

Yanagi

Takada

et al. 2023

Journal of Allergy and Clinical Immunology

View full text Add to dashboard Cite

“…EGIDs are an umbrella term referring to primary eosinophilic disorders of the gastrointestinal tract encompassing a spectrum of diseases characterized by prominent eosinophilic inflammation affecting different regions of the gut (i.e., esophagus, stomach, small bowel, and colon or a combination) that occur in the absence of secondary causes (e.g., infections and drug reactions) [ 23 , 24 ]. The strong association of EGID with allergic disorders such as asthma, dermatitis, rhinitis, and food or drug allergies has been recently recognized, and although their shared pathophysiological basis remains partly elusive (e.g., both are characterized by immunologically Th2 responses and allergic sensitizations), this feature may impact on accurate diagnostic and treatment of these conditions [ 6 , 24 ].…”

Section: Literature Reviewmentioning

confidence: 99%

The Role of Benralizumab in Eosinophilic Immune Dysfunctions: A Case Report-Based Literature Review

Gomes

Mendes

Ferreira

et al. 2023

Case Reports in Medicine

View full text Add to dashboard Cite

In the past years, the knowledge of eosinophils playing a primary pathophysiologic role in several associated conditions has led to the development of biologics targeting therapies aiming at normalizing the immune response, reducing chronic inflammation, and preventing tissue damage. To better illustrate the potential relationship between different eosinophilic immune dysfunctions and the effects of biological therapies in this scenario, here, we present a case of a 63-year-old male first referred to our department in 2018 with a diagnosis of asthma, polyposis, and rhinosinusitis and presenting a suspicion of nonsteroidal anti-inflammatory drugs’ allergy. He also had a past medical history of eosinophilic gastroenteritis/duodenitis (eosinophilia counts >50 cells/high-power field HPF). The use of multiple courses of corticosteroid therapy failed to completely control these conditions. In October 2019, after starting benralizumab (an antibody directed against the alpha chain of the IL-5 cytokine receptor) as add-on treatment for severe eosinophilic asthma, important clinical improvements were reported both on the respiratory (no asthma exacerbations) and gastrointestinal systems (eosinophilia count 0 cells/HPF). Patients’ quality of life also increased. Since June 2020, systemic corticosteroid therapy was reduced without worsening of gastrointestinal symptoms or eosinophilic inflammation. This case warns of the importance of early recognition and appropriate individualized treatment of eosinophilic immune dysfunctions and suggests the conduction of further larger studies on the use of benralizumab in gastrointestinal syndromes aiming at better understanding its relying mechanisms of action in the intestinal mucosa.

show abstract

“…To the Editor, Eosinophilic gastrointestinal diseases (EGIDs) encompass eosinophilic esophagitis (EoE) and non-EoE-EGIDs that include eosinophilic gastritis (EoG), eosinophilic enteritis (EoN), and eosinophilic colitis (EoC). 1 They refer to a spectrum of clinical diseases that present with variable degrees of infiltration of the gastrointestinal tract by eosinophils in the absence of other known causes of tissue eosinophilia. Clinical manifestations and laboratory findings are usually nonspecific and may occasionally be associated with peripheral blood eosinophilia.…”

Section: Dupilumab Treatment Of Eosinophilic Gastrointestinal Disease...mentioning

confidence: 99%